lots of reasons and variables on the private placement and everybody here have given their opinions but, in my opinion this was simply terrible. I've been trading and doing analysis for 30 years and I believe MF jumped on the first offer; not because he wanted to but because he had to in order to fund the research and the trial. The most recent funding has come from diluting it's shareholders through (ATM) a lot of start-ups do and it stands for at-the-market, as in “at-the-market offerings.” In an ATM, a listed company sells newly issued shares incrementally into the existing trading marketing through a broker-dealer, at market prices. I've calculated the last 30 trading days and Revive averaged $0.61 and MF does a placement @ $0.50 ? Let's go with that, but the warrants @ $0.70 people for 36 months; come on. This was a gift to Canaccord Genuity Corp. and Leede Jones Gable Inc. The price has rebounded which is positive but I'm sorry the timing of this deal goes to show that the CEO is a rookie and potentially padded the pockets of a few buddies over at Canaccord. I'm a shareholder and like the direction the company is going but this sucks for all of us longs. The bulls here will strongly disagree with my opinion and convince you otherwise but the facts are the facts; take the blinders off and look at the structure of this placement.
The December 23rd. news release that stated:
"The Company’s clinical safety team has actively monitored the ongoing interim data of patients and found there have been no safety concerns and no severe adverse events during the interim analysis enrollment period"
Revive has had a lot of positive news releases and recent hiring's being subject matter experts to do such a low offering.
